Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.
BACKGROUND: Chronic heart failure (CHF) is a major cause of morbidity and mortality that requires a novel approach to therapy. Perhexiline is an antianginal drug that augments glucose metabolism by blocking muscle mitochondrial free fatty acid uptake, thereby increasing metabolic efficiency. We asse...
Prif Awduron: | Lee, L, Campbell, R, Scheuermann-Freestone, M, Taylor, R, Gunaruwan, P, Williams, L, Ashrafian, H, Horowitz, J, Fraser, A, Clarke, K, Frenneaux, M |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
2005
|
Eitemau Tebyg
-
Augmentation of glucose metabolism with perhexiline in non-ischaemic heart failure
gan: Lee, L, et al.
Cyhoeddwyd: (2004) -
Perhexiline.
gan: Ashrafian, H, et al.
Cyhoeddwyd: (2007) -
Effects of perhexiline on ketone body and triglyceride synthesis in patients with refractory angina or heart failure
gan: Shivu, G, et al.
Cyhoeddwyd: (2008) -
Metabolic modulator perhexiline corrects energy deficiency and improves exercise capacity in symptomatic hypertrophic cardiomyopathy.
gan: Abozguia, K, et al.
Cyhoeddwyd: (2010) -
Metabolic Modulation With Perhexiline Corrects Energy Deficiency and Improves Exercise Capacity in Symptomatic Hypertrophic Cardiomyopathy
gan: Abozguia, K, et al.
Cyhoeddwyd: (2009)